Business Context and Reporting Period
GX Acquisition Corp. filed this Form 8-K on July 14, 2021, reporting results of a special stockholder meeting related to its proposed business combination with Celularity Operations Inc. (formerly Celularity Inc.). The transaction was intended to result in Celularity becoming a wholly owned subsidiary of GX, with GX subsequently changing its name to Celularity Inc.
This filing is not a financial-results report and does not provide operating-period revenue, earnings, cash-flow, or balance-sheet statements.
Key Financial and Capitalization Information
- Stockholders holding 9,174,705 Class A common shares elected to redeem their shares.
- The redemption price was approximately $10.20 per share.
- Approximately $93.6 million was expected to be withdrawn from the Trust Account to fund the redemptions.
- The filing does not provide a clear post-redemption cash balance, debt balance, liquidity forecast, revenue, profit, cash flow, or margin data.
Material Changes Versus the Prior Comparable Period
- No comparable-period financial information is presented.
- Stockholders approved the business combination and related charter amendments, including increasing authorized common shares to 730,000,000 and preferred shares to 10,000,000.
- Stockholders approved changing the registrant’s name from GX Acquisition Corp. to Celularity Inc., effective upon closing of the business combination.
- Stockholders approved the issuance of shares to Celularity stockholders and private-placement investors in connection with the transaction.
- Stockholders approved an equity incentive plan, an employee stock purchase plan, and the election of nine directors to serve upon closing.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide management revenue or earnings guidance.
- Completion of the business combination and the related corporate changes remained dependent on consummation of the transaction.
- The approximately $93.6 million redemption reduced the cash available in the Trust Account and is a material financing and liquidity item.
- The filing does not provide a clear description of remaining transaction contingencies, financing conditions, or the expected impact of the redemptions on post-closing liquidity.
Special Meeting Voting Results
| Proposal | For | Against | Abstain |
|---|---|---|---|
| Business combination | 14,241,615 | 1,503,835 | 52,044 |
| Authorized share increase | 14,170,201 | 1,537,482 | 89,811 |
| Proposed charter and name change | 14,178,264 | 1,533,574 | 85,656 |
| Equity incentive plan | 14,193,973 | 1,524,540 | 78,981 |
| Employee stock purchase plan | 14,209,397 | 1,509,106 | 78,991 |
| Share issuance approval | 14,219,568 | 1,503,835 | 74,091 |
Important Facts for Investors to Verify
- Verify the closing date and final terms of the GX-Celularity business combination.
- Verify the final number of shares redeemed and the post-redemption Trust Account balance.
- Review the definitive merger documents and private-placement terms to assess dilution and ownership changes.
- Confirm Celularity’s post-closing cash needs, debt, operating losses, and liquidity outlook in subsequent filings.
- Verify the effectiveness of the name change, new charter, board composition, and approved equity plans.